LIPO 最新10-Q变化
将 LIPO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2025-11-14 与上一份 10-Q · 2025-08-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +24 | −23 | ~12 | 80 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 2 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 文字有新增/删除 | 0 | 0 | ~4 | 10 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2025-11-14
● our ability to raise additional capital will be more difficult as a company whose common stock is traded on the OTC markets;
● if we are unable to raise additional capital, we may be forced to curtail or cease operations or file for bankruptcy protection or pursue a dissolution and liquidation of all of our remaining assets;
On October 3, 2025, Dr. Michael Chancellor notified the Company of his intention to retire from his positions as the Company’s Chief Medical Officer and a member of the Company’s Board of Directors, effective December 4, 2025.
Comparison of the Three Months Ended September 30, 2025 and 2024
The following table summarizes our results of operations for the three months ended September 30, 2025 and 2024 (in thousands):
相对上期删除的文字 · 来源:10-Q · 2025-08-14
Dr. Jonathan Kaufman, our Chief Executive Officer, and Dr. Michael Chancellor, our Chief Medical Officer, co-founded the Company in 2005. On December 22, 2022, we completed our initial public offering, receiving approximately $5.0 million in aggregate net proceeds. Our principal executive offices ar…
On April 4, 2025, we entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC (“Wainwright”) to sell shares of Common Stock having an aggregate offering price of up to $2,641,881, from time to time, through an “at the market offering” program under which Wainwright will act a…
On April 8, 2025, we filed a Certificate of Amendment (the “Series C Certificate of Amendment”) to the Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock (the “Series C Certificate of Designation”) with the Secretary of State of the State…
As previously disclosed, on May 12, 2025, we received a written notification (the “May Letter”) from the Listing Qualifications Department (the “Staff”) notifying us that the Staff determined that we failed to comply with Nasdaq’s shareholder approval and voting rights requirements in connection wit…
On June 20, 2025, we received a letter (the “June Letter”) from the Panel indicating that the Panel had determined to delist the Common Stock from the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5100, which permits Nasdaq to use its discretionary authority for public interest concerns, due…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议